Back to Cell Types

VMRC-RCZHomo sapiens (Human)Cancer cell line

Also known as: Virginia Mason Research Center-Renal Cancer Z, VMRCRCZ, VMRC-PCZ

🤖 AI SummaryBased on 7 publications

Quick Overview

Human renal cell carcinoma cell line with potential for research in cancer genomics and drug sensitivity.

Detailed Summary

VMRC-RCZ is a human renal cell carcinoma (RCC) cell line derived from a renal tumor. It is used in research to study the genomic characteristics of RCC, particularly in relation to copy number alterations (CNAs) and mutations in key cancer genes. This cell line has been analyzed in the context of the Cancer Cell Line Encyclopedia (CCLE) and the Cancer Genome Atlas (TCGA) to understand its similarity to different RCC subtypes. VMRC-RCZ has been noted for its genomic features, including the absence of 3p loss, which is a common feature in many RCC cell lines. It is also part of studies investigating the role of specific genes like PARD3 and its implications in cell polarity and tumor progression. The cell line is utilized in studies related to drug sensitivity and resistance, contributing to the development of targeted therapies for RCC.

Research Applications

Genomic analysis of renal cell carcinomaCopy number alteration studiesMutation profiling in cancer genesDrug sensitivity and resistance research

Key Characteristics

Absence of 3p lossPart of CCLE and TCGA analysesUsed in studies of PARD3 and cell polarity

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1791
Species	Homo sapiens (Human)

Donor Information

Age Category	Unknown
Sex	Unknown
Race	asian

Disease Information

Disease	Renal cell carcinoma
Lineage	Kidney
Subtype	Renal Cell Carcinoma
OncoTree Code	RCC

DepMap Information

Source Type	HSRRB
Source ID	ACH-000171_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	VHL	c.463+2T>C	Heterozygous	Splice donor mutation	Unknown, Unknown
MutationSimple	TP53	p.Asp48Valfs*74 (c.143_146del4)	Heterozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,12

D13S317

13

D16S539

11

D5S818

11,12

D7S820

10,11

TH01

9.3

TPOX

8

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.

Hsieh J.J.-D., Hakimi A.A.

Nat. Commun. 8:15165.1-15165.10(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines.

Nakatani Y., Hosaka M.

Int. J. Cancer 91:219-224(2001).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma.

Mishina M., Habuchi T., Takahashi R., Sugiyama T., Yoshida O.

Jpn. J. Cancer Res. 86:795-799(1995).